Portola Pharmaceuticals   Print Page    Close Window

Corporate Profile

Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor, and An... Read More

Stock Quote
NASDAQ PTLA (Common Stock)
$40.28 + 0.04
Stock chart for: PTLA.O.  Currently trading at $40.28 with a 52 week high of $67.10 and a 52 week low of $30.10.
07/16/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Upcoming EventsMore >>
There are currently no events scheduled.
Archived Events
Portola Pharmaceuticals, Inc. at William Blair 38th Annual Growth Stock Conference
Wednesday, June 13, 2018 12:40 p.m. CT
LocationChicago, IL
Supporting Materials
Download Event Supporting Material Portola Presentation - William Blair Growth Stock Conference

Portola Pharmaceuticals, Inc. at Goldman Sachs 39th Annual Global Healthcare Conference
Tuesday, June 12, 2018 9:20 a.m. PT
LocationRancho Palos Verdes, CA